ARTICLE | Company News
FDA accepts Boehringer tiotropium/olodaterol NDA
August 20, 2014 1:47 AM UTC
Boehringer Ingelheim GmbH (Ingelheim, Germany) said FDA accepted for review an NDA for a once-daily, fixed-dose combination of tiotropium/olodaterol delivered via the company's Respimat soft mist inhaler to treat chronic obstructive pulmonary disorder (COPD). Boehringer could not be reached for a PDUFA date. ...